Eli Lilly and Company (NYSE: LLY) has received approval from the U.S. Nuclear Regulatory Commission (“NRC”) for the transfer of control of POINT Biopharma Global Inc.’s (NASDAQ: PNT) radioactive materials license. This follows Lilly’s tender offer to acquire all outstanding shares of POINT at $12.50 per share. The NRC Consent marks the final regulatory step needed for the transaction’s completion. The tender offer deadline is Nov. 16, 2023, with Georgeson LLC available for inquiries or assistance at 1-800-932-9864 or Pointbiopharma@georgeson.com.
Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Nuclear Regulatory Commission (“NRC”) has issued its consent for the indirect transfer of control of POINT Biopharma Global Inc.’s (NASDAQ: PNT) radioactive materials license (the “NRC Consent”), which will occur following the completion of Lilly’s previously announced tender offer to acquire all of the issued and outstanding shares (“Shares”) of common stock of POINT, for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding. Obtaining the NRC Consent is the last regulatory approval necessary for the consummation of the transaction.
The tender offer is scheduled to expire at 5:00 p.m., Eastern time, on Nov. 16, 2023, unless the tender offer is further extended or earlier terminated. Questions or requests for assistance may be directed to Georgeson LLC, the information agent for the tender offer, by calling toll-free 1-800-932-9864 or via email to Pointbiopharma@georgeson.com.
Source: Biospace
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
